In yesterday’s Wall Street session, Surface Oncology Inc. (NASDAQ:SURF) shares traded at $1.03, up 3.00% from the previous session.
As of this writing, 6 analysts cover Surface Oncology Inc. (NASDAQ:SURF). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $3.00, we find $6.00. Given the previous closing price of $1.00, this indicates a potential upside of 500.0 percent. SURF stock price is now 12.68% away from the 50-day moving average and -31.28% away from the 200-day moving average. The market capitalization of the company currently stands at $63.65M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $5.40 as their price target over the next twelve months.
With the price target of $17, BTIG Research recently initiated with Buy rating for Surface Oncology Inc. (NASDAQ: SURF). On September 04, 2020, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $11, while ‘Wedbush’ rates the stock as ‘Outperform’.
In other news, ONEILL ALISON, Chief Medical Officer sold 4,463 shares of the company’s stock on Aug 03. The stock was sold for $7,676 at an average price of $1.72. Upon completion of the transaction, the Chief Medical Officer now directly owns 63,728 shares in the company, valued at $65639.84. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 03, Chief Business Officer RATH HENRY C. sold 5,676 shares of the business’s stock. A total of $9,763 was realized by selling the stock at an average price of $1.72. This leaves the insider owning 32,324 shares of the company worth $33293.72. Insiders disposed of 31,176 shares of company stock worth roughly $32111.280000000002 over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SURF stock. A new stake in Surface Oncology Inc. shares was purchased by NIKKO ASSET MANAGEMENT AMERICAS, INC. during the first quarter worth $1,137,000. SUMITOMO MITSUI TRUST HOLDINGS, INC. invested $1,137,000 in shares of SURF during the first quarter. In the first quarter, CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in Surface Oncology Inc. valued at approximately $101,000. MAN GROUP PLC acquired a new stake in SURF for approximately $14,000. BALYASNY ASSET MANAGEMENT LLC purchased a new stake in SURF valued at around $11,000 in the second quarter. In total, there are 118 active investors with 53.50% ownership of the company’s stock.
Monday morning saw Surface Oncology Inc. (NASDAQ: SURF) opened at $1.0000. During the past 12 months, Surface Oncology Inc. has had a low of $0.60 and a high of $4.05. As of last week, the company has a debt-to-equity ratio of 0.23, a current ratio of 8.30, and a quick ratio of 8.30. The fifty day moving average price for SURF is $0.9141 and a two-hundred day moving average price translates $1.4989 for the stock.
The latest earnings results from Surface Oncology Inc. (NASDAQ: SURF) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.46, inline with analysts’ expectations of -$0.46. This compares to -$0.44 EPS in the same period last year. For the current quarter, analysts expect SURF to generate $80k in revenue.
Surface Oncology Inc.(SURF) Company Profile
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
